Equities analysts predict that Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will post earnings of ($0.04) per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Amphastar Pharmaceuticals’ earnings. The highest EPS estimate is $0.10 and the lowest is ($0.30). Amphastar Pharmaceuticals posted earnings per share of $0.01 during the same quarter last year, which suggests a negative year over year growth rate of 500%. The business is scheduled to report its next earnings report on Monday, March 12th.

On average, analysts expect that Amphastar Pharmaceuticals will report full year earnings of $0.23 per share for the current year, with EPS estimates ranging from ($0.03) to $0.38. For the next year, analysts expect that the business will report earnings of $0.57 per share, with EPS estimates ranging from $0.11 to $0.86. Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.05. Amphastar Pharmaceuticals had a return on equity of 0.21% and a net margin of 0.30%. The business had revenue of $57.90 million during the quarter, compared to analysts’ expectations of $57.23 million. During the same period in the previous year, the company posted $0.14 earnings per share. The firm’s revenue for the quarter was down 9.8% compared to the same quarter last year.

Several equities research analysts have weighed in on the company. BMO Capital Markets upped their target price on Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the stock a “market perform” rating in a research note on Friday. Zacks Investment Research cut Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Piper Jaffray Companies set a $19.00 target price on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, October 22nd. Wells Fargo & Company restated a “buy” rating on shares of Amphastar Pharmaceuticals in a research note on Saturday, July 22nd. Finally, Jefferies Group LLC set a $19.00 target price on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, October 29th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. Amphastar Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $20.43.

In related news, EVP Diane G. Gerst sold 8,444 shares of the stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $18.87, for a total value of $159,338.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael A. Zasloff sold 63,624 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $18.18, for a total value of $1,156,684.32. Following the completion of the sale, the director now owns 101,879 shares of the company’s stock, valued at $1,852,160.22. The disclosure for this sale can be found here. Insiders have sold 155,285 shares of company stock valued at $2,857,895 over the last quarter. Company insiders own 11.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of AMPH. Dimensional Fund Advisors LP increased its holdings in Amphastar Pharmaceuticals by 25.5% in the second quarter. Dimensional Fund Advisors LP now owns 1,331,842 shares of the company’s stock valued at $23,786,000 after purchasing an additional 270,654 shares during the period. Vanguard Group Inc. grew its holdings in Amphastar Pharmaceuticals by 10.8% during the 2nd quarter. Vanguard Group Inc. now owns 2,414,797 shares of the company’s stock worth $43,128,000 after acquiring an additional 235,033 shares during the period. UBS Asset Management Americas Inc. grew its holdings in Amphastar Pharmaceuticals by 143.0% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 362,947 shares of the company’s stock worth $6,482,000 after acquiring an additional 213,572 shares during the period. Citigroup Inc. grew its holdings in Amphastar Pharmaceuticals by 295.1% during the 2nd quarter. Citigroup Inc. now owns 221,729 shares of the company’s stock worth $3,960,000 after acquiring an additional 165,613 shares during the period. Finally, State Street Corp grew its holdings in Amphastar Pharmaceuticals by 11.1% during the 1st quarter. State Street Corp now owns 1,062,439 shares of the company’s stock worth $15,406,000 after acquiring an additional 106,448 shares during the period. Institutional investors and hedge funds own 43.89% of the company’s stock.

Amphastar Pharmaceuticals (AMPH) traded down $0.69 during midday trading on Friday, reaching $17.86. The company’s stock had a trading volume of 229,400 shares, compared to its average volume of 294,612. The company has a quick ratio of 1.86, a current ratio of 3.08 and a debt-to-equity ratio of 0.13. Amphastar Pharmaceuticals has a 12-month low of $12.05 and a 12-month high of $21.75. The company has a market capitalization of $821.13, a PE ratio of 123.67, a PEG ratio of 8.24 and a beta of 1.68.

Amphastar Pharmaceuticals declared that its Board of Directors has initiated a stock repurchase program on Wednesday, August 9th that authorizes the company to buyback $20.00 million in shares. This buyback authorization authorizes the company to purchase up to 2.8% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its shares are undervalued.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Anticipate Amphastar Pharmaceuticals, Inc. (AMPH) to Announce -$0.04 Earnings Per Share” was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/zacks-brokerages-anticipate-amphastar-pharmaceuticals-inc-amph-to-announce-0-04-earnings-per-share/1703047.html.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.